OTTAWA, Sept. 16, 2011 /CNW/ - The following is a statement by Russell Williams, President of Canada's
Research-Based Pharmaceutical Companies (Rx&D), to celebrate today's
grand opening of the International Vaccine Centre (InterVac) by the
Vaccine and Infectious Disease Organization and the University of
"Rx&D congratulates the Vaccine and Infectious Disease Organization
(VIDO) and the University of Saskatchewan on the opening of the world's
most advanced containment facility. InterVac's state of-the-art vaccine
development will help to address global health issues by contributing
to the next generation of innovative vaccines. It will also keep Canada
at the forefront of innovative science by training scientists and
students from around the world and build upon our national legacy in
vaccine development that stretches over a century.
"The Government of Canada's investment demonstrates their commitment to
innovation and the development of important new vaccines. It will
support research to improve the health of Canadians, strengthen
Canada's technology and knowledge infrastructure and generate
high-skilled research jobs.
"Each year vaccines save an estimated three million lives world-wide.
Rx&D believes we have only begun to harness their full potential and
through the efforts of VIDO and Intervac they hold the promise for a
healthier and more prosperous future."
Rx&D is the association of leading research-based pharmaceutical
companies dedicated to improving the health of Canadians through the
discovery and development of new medicines and vaccines. Our community
represents 15,000 men and women working for 50 member companies and
invests more than $1 billion in research and development each year to
fuel Canada's knowledge-based economy. Guided by our Code of Ethical
Practices, our membership is committed to working in partnership with
governments, healthcare professionals and stakeholders in a highly
SOURCE CANADA'S RESEARCH-BASED PHARMACEUTICAL COMPANIES (RX
For further information: